Aberdeen Group Boosts Stake in ProQR Therapeutics

Institutional investor increases holdings in biopharmaceutical company by 28.4% in Q4 2025

Apr. 9, 2026 at 7:22am

Got story updates? Submit your updates here. ›

An extreme close-up of a series of interconnected mechanical and electronic components, representing the intricate financial systems and processes that drive institutional investment in the biopharmaceutical sector.The complex financial infrastructure behind institutional investment decisions that shape the biotech industry.Cambridge Today

Aberdeen Group plc, a major institutional investor, increased its stake in ProQR Therapeutics N.V. (NASDAQ:PRQR) by 28.4% during the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund now owns 2,950,676 shares of the biopharmaceutical company's stock, valued at approximately $5.96 million.

Why it matters

The increased investment by Aberdeen Group, a prominent institutional investor, signals confidence in ProQR Therapeutics' potential and its pipeline of RNA-based therapies for severe genetic diseases. This news could impact the company's stock price and attract further institutional interest.

The details

According to the 13F filing, Aberdeen Group acquired an additional 651,853 shares of ProQR Therapeutics during the fourth quarter, bringing its total stake in the company to 2,950,676 shares. This represents approximately 2.80% of ProQR's outstanding shares. The investment firm's increased position in the biopharmaceutical company suggests it sees value in ProQR's research and development efforts, which are focused on developing innovative RNA-based treatments for conditions like Leber congenital amaurosis, Usher syndrome, and dystrophic epidermolysis bullosa.

  • Aberdeen Group filed its 13F report with the SEC on April 9, 2026, disclosing its Q4 2025 holdings.
  • The fourth quarter of 2025 ended on December 31, 2025.

The players

Aberdeen Group plc

A major institutional investor and asset management firm that has increased its stake in ProQR Therapeutics, a biopharmaceutical company focused on developing RNA-based therapies for severe genetic diseases.

ProQR Therapeutics N.V.

A clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases, including Leber congenital amaurosis, Usher syndrome, and dystrophic epidermolysis bullosa.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Aberdeen Group in ProQR Therapeutics reflects the institutional investor's confidence in the company's RNA-based therapy pipeline and its potential to address unmet medical needs in rare genetic disorders. This news could signal growing interest from the investment community in ProQR's innovative approach to drug development.